NCT00171795View on ClinicalTrials.gov

Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment

PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Traumatic Brain Injury
Interventions
DRUG

Rivastigmine

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00171795 - Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment | Biotech Hunter | Biotech Hunter